Source: GlobeNewswire

Press Release: LogicBio Therapeutics : LogicBio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases, today reported financial results and provided a corporate update for the fourth quarter and full year ended December 31, 2018.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Frederic Chereau's photo - President & CEO of LogicBio

President & CEO

Frederic Chereau

CEO Approval Rating

82/100

LogicBio is a biotechnology company that develops genetic medicines to treat rare pediatric diseases. Read more